Biomarkers of drugs targeting HER-family signalling in cancer

Journal of Pathology

Volumn 232, Issue 2, 2014, Pages 219-229

  Montemurro, Filippo ^a   Scaltriti, Maurizio ^b  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

biologically targeted therapy; biomarker; breast cancer; gastric cancer; HER1 EGFR; HER2 neu; HER3

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC METAL COMPLEX; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; FLUOROURACIL; GEFITINIB; LAPATINIB; LETROZOLE; NERATINIB; NEU DIFFERENTIATION FACTOR; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN BCL 2; PROTEIN S6; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TOPOISOMERASE 2A; TRANSCRIPTION FACTOR GATA 3; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; GENE MUTATION; HUMAN; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

BIOLOGICALLY TARGETED THERAPY; BIOMARKER; BREAST CANCER; GASTRIC CANCER; HER1/EGFR; HER2/NEU; HER3;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DISCOVERY; FEMALE; HUMANS; MALE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84890280905     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4269     Document Type: Review

References (127)

1. Zwick E, Bange J, Ullrich A,. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 2001; 8: 161-173.
2. Ullrich A, Schlessinger J,. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-212.
3. Jones JT, Akita RW, Sliwkowski MX,. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 1999; 447: 227-231.
4. Kochupurakkal BS, Harari D, Di-Segni A, et al., Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J Biol Chem 2005; 280: 8503-8512.
5. Citri A, Yarden Y,. EGF-ERBB signalling: towards the systems level. Nature Rev Mol Cell Biol 2006; 7: 505-516.
6. Olayioye MA, Neve RM, Lane HA, et al., The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-3167.
7. Yarden Y, Sliwkowski MX,. Untangling the ErbB signalling network. Nature Rev Mol Cell Biol 2001; 2: 127-137.
8. Sergina NV, Rausch M, Wang D, et al., Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445: 437-441.
9. Tzahar E, Waterman H, Chen X, et al., A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16: 5276-5287.
10. Pinkas-Kramarski R, Soussan L, Waterman H, et al., Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996; 15: 2452-2467.
11. Altman DG, McShane LM, Sauerbrei W, et al., Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med 2012; 9: e1001216.
12. Slamon DJ, Clark GM, Wong SG, et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
13. Slamon DJ, Godolphin W, Jones LA, et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
14. Montemurro F, Valabrega G, Aglietta M,. Trastuzumab-based combination therapy for breast cancer. Expert Opin Pharmacother 2004; 5: 81-96.
15. Montemurro F, Valabrega G, Aglietta M,. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 2007; 7: 257-268.
16. Baselga J, Cortes J, Kim SB, et al., Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119.
17. Verma S, Miles D, Gianni L, et al., Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791.
18. Valabrega G, Montemurro F, Aglietta M,. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18: 977-984.
19. Rexer BN, Arteaga CL,. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog 2012; 17: 1-16.
20. Baselga J, Verma C, Ro J, et al., Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer. ACCR Annual Meeting 2013; abstract LB-63.
21. Baselga J, Cortes J, Im S-A, et al., Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Cancer Res 2012; 72: abstract S5-1.
22. Gianni L, Bianchini G, Kiermaier A, et al., S5-1: Neoadjuvant pertuzumab (P) and trastuzumab (H): biomarker analyses of a 4-arm randomized phase II study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC). Cancer Res 2012; 71: abstract S5-1.
23. Schneeweiss A, Chia S, Hegg R, et al., Biomarker (BM) analyses of a phase II study of neoadjuvant pertuzumab and trastuzumab with and without anthracycline (ATC)-containing chemotherapy for treatment of HER2-positive early breast cancer (BC) (TRYPHAENA). Ann Oncol 2012; 23: abstract 202P.
24. Hanna WM, Ruschoff J, Bilous M, et al., HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol 2013; DOI 10.1038/modpathol.2013.103.
25. Wolff AC, Hammond ME, Hicks DG, et al., Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997-4013.
26. Shi Y, Huang W, Tan Y, et al., A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol 2009; 18: 11-21.
27. Lipton A, Kostler WJ, Leitzel K, et al., Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer 2010; 116: 5168-5178.
28. Ghosh R, Narasanna A, Wang SE, et al., Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res 2011; 71: 1871-1882.
29. Arribas J, Baselga J, Pedersen K, et al., p95HER2 and breast cancer. Cancer Res 2011; 71: 1515-1519.
30. Scaltriti M, Rojo F, Ocana A, et al., Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007; 99: 628-638.
31. Pedersen K, Angelini PD, Laos S, et al., A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol 2009; 29: 3319-3331.
32. Parra-Palau JL, Pedersen K, Peg V, et al., A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers. Cancer Res 2010; 70: 8537-8546.
33. Sperinde J, Jin XG, Banerjee J, et al., Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res 2010; 16: 4226-4235.
34. Loibl S, Bruey J, Von Minckwitz G, et al., Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: a translational investigation from the neoadjuvant GeparQuattro study. ASCO Meeting Abstracts 2011; 29: abstract 530.
35. Scaltriti M, Nuciforo B, Bradbury I, et al., High HER2 expression correlates with response to trastuzumab and lapatinib in the NeoALTTO phase III trial. 36th San Antonio Breast Cancer Symposium 2013; Poster P1-08-42.
36. She QB, Chandarlapaty S, Ye Q, et al., Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008; 3: e3065.
37. Brachmann SM, Hofmann I, Schnell C, et al., Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A 2009; 106: 22299-22304.
38. Kang S, Bader AG, Vogt PK,. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 2005; 102: 802-807.
39. Samuels Y, Wang Z, Bardelli A, et al., High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
40. Miller TW, Rexer BN, Garrett JT, et al., Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011; 13: 224.
41. Isakoff SJ, Engelman JA, Irie HY, et al., Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005; 65: 10992-11000.
42. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
43. Carpten JD, Faber AL, Horn C, et al., A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448: 439-444.
44. Gewinner C, Wang ZC, Richardson A, et al., Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009; 16: 115-125.
45. Sun H, Lesche R, Li DM, et al., PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A 1999; 96: 6199-6204.
46. Wu X, Senechal K, Neshat MS, et al., The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1998; 95: 15587-15591.
47. Wang L, Zhang Q, Zhang J, et al., PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 2011; 11: 248.
48. Eichhorn PJ, Gili M, Scaltriti M, et al., Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68: 9221-9230.
49. Berns K, Horlings HM, Hennessy BT, et al., A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12: 395-402.
50. Garcia-Garcia C, Ibrahim YH, Serra V, et al., Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res 2012; 18: 2603-2612.
51. Nagata Y, Lan KH, Zhou XY, et al., PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-127.
52. Jensen JD, Knoop A, Laenkholm AV, et al., PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 2012; 23: 2034-2042.
53. Cizkova M, Dujaric ME, Lehmann-Che J, et al., Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer 2013; 108: 1807-1809.
54. Razis E, Bobos M, Kotoula V, et al., Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 2011; 128: 447-456.
55. Perez EA, Dueck AC, McCullough AE, et al., Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol 2013; 31: 2115-2122.
56. Loi S, Michiels S, Lambrechts D, et al., Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst 2013; 105: 960-967.
57. Dave B, Migliaccio I, Gutierrez MC, et al., Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 2011; 29: 166-173.
58. Serra V, Markman B, Scaltriti M, et al., NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68: 8022-8030.
59. Ritter CA, Perez-Torres M, Rinehart C, et al., Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007; 13: 4909-4919.
60. Wang SE, Xiang B, Guix M, et al., Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 2008; 28: 5605-5620.
61. Arteaga CL, O'Neill A, Moulder SL, et al., A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res 2008; 14: 6277-6283.
62. Wilson TR, Fridlyand J, Yan Y, et al., Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487: 505-509.
63. Garrett JT, Olivares MG, Rinehart C, et al., Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 2011; 108: 5021-5026.
64. Amin DN, Sergina N, Ahuja D, et al., Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med 2010; 2: 16ra17.
65. Chandarlapaty S, Sawai A, Scaltriti M, et al., AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011; 19: 58-71.
66. Serra V, Scaltriti M, Prudkin L, et al., PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011; 30: 2547-2557.
67. Wilson TR, Lee DY, Berry L, et al., Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 2011; 20: 158-172.
68. Gianni L, Pienkowski T, Im YH, et al., Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32.
69. Baselga J, Bradbury I, Eidtmann H, et al., Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-640.
70. Montemurro F, Rossi V, Cossu Rocca M, et al., Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer 2012; 118: 17-26.
71. Carey LA, Berry DA, Ollila D, et al., Clinical and translational results of CALGB 40601: a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. ASCO Meeting Abstracts 2013; 31: abstract 500.
72. Xia W, Bacus S, Hegde P, et al., A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 2006; 103: 7795-7800.
73. Liu L, Greger J, Shi H, et al., Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009; 69: 6871-6878.
74. Rimawi MF, Mayer IA, Forero A, et al., Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol 2013; 31: 1726-1731.
75. Perou CM, Sorlie T, Eisen MB, et al., Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
76. Sorlie T, Tibshirani R, Parker J, et al., Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418-8423.
77. Parker JS, Mullins M, Cheang MC, et al., Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
78. Reis-Filho JS, Pusztai L,. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011; 378: 1812-1823.
79. Curtis C, Shah SP, Chin SF, et al., The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
80. Weigelt B, Mackay A, A'hern R, et al., Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010; 11: 339-349.
81. Mackay A, Weigelt B, Grigoriadis A, et al., Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst 2011; 103: 662-673.
82. Haibe-Kains B, Desmedt C, Loi S, et al., A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst 2012; 104: 311-325.
83. Geyer FC, Rodrigues DN, Weigelt B, et al., Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv Anat Pathol 2012; 19: 39-53.
84. Goldhirsch A, Winer EP, Coates AS, et al., Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-2223.
85. Guiu S, Michiels S, André F, et al., Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 2012; 23: 2997-3006.
86. Vaz-Luis I, Winer EP, Lin NU,. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol 2013; 24: 283-291.
87. Montemurro F, Di Cosimo S, Arpino G,. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol 2013; DOI: 10.1093/annonc/mdt287.
88. Arpino G, Wiechmann L, Osborne CK, et al., Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008; 29: 217-233.
89. Leary AF, Drury S, Detre S, et al., Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 2010; 16: 1486-1497.
90. Guix M, Granja Nde M, Meszoely I, et al., Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol 2008; 26: 897-906.
91. Polychronis A, Sinnett HD, Hadjiminas D, et al., Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 2005; 6: 383-391.
92. Cristofanilli M, Valero V, Mangalik A, et al., Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010; 16: 1904-1914.
93. Osborne CK, Neven P, Dirix LY, et al., Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 2011; 17: 1147-1159.
94. Johnston S, Pippen J Jr, Pivot X, et al., Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27: 5538-5546.
95. Carey L, Winer E, Viale G, et al., Triple-negative breast cancer: disease entity or title of convenience? Nature Rev Clin Oncol 2010; 7: 683-692.
96. Carey LA, Rugo HS, Marcom PK, et al., TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30: 2615-2623.
97. Baselga J, Gomez P, Greil R, et al., Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31: 2586-2592.
98. Shigematsu H, Takahashi T, Nomura M, et al., Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005; 65: 1642-1646.
99. Lee JW, Soung YH, Seo SH, et al., Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 2006; 12: 57-61.
100. Bose R, Kavuri SM, Searleman AC, et al., Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013; 3: 224-237.
101. Bose P, Ozer H,. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Invest Drugs 2009; 18: 1735-1751.
102. Bargmann CI, Hung MC, Weinberg RA,. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986; 45: 649-657.
103. Serra V, Vivancos A, Puente XS, et al., Clinical response to a lapatinib-based therapy of a Li-Fraumeni syndrome patient with a novel HER2-V659E mutation. Cancer Discov 2013; DOI 10.1158/2159-8290.CD-13-0132.
104. Yonemura Y, Ninomiya I, Yamaguchi A, et al., Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991; 51: 1034-1038.
105. Gravalos C, Jimeno A,. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-1529.
106. Gong SJ, Jin CJ, Rha SY, et al., Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett 2004; 214: 215-224.
107. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, et al., Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007; 59: 795-805.
108. Wainberg ZA, Anghel A, Desai AJ, et al., Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010; 16: 1509-1519.
109. Yamashita-Kashima Y, Iijima S, Yorozu K, et al., Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 2011; 17: 5060-5070.
110. Barok M, Tanner M, Koninki K, et al., Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 2011; 306: 171-179.
111. Yamashita-Kashima Y, Shu S, Harada N, et al., Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model. Oncol Rep 2013; 30: 1087-1093.
112. Shiraishi K, Mimura K, Izawa S, et al., Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity. Gastric Cancer 2012; 16: 571-580.
113. Bang YJ, Van Cutsem E, Feyereislova A, et al., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
114. Hofmann M, Stoss O, Shi D, et al., Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805.
115. Bang Y-J., A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study. ASCO Meeting Abstracts 2013; 31: abstract 11.
116. Hecht JR, Bang Y-J, Qin S, et al., Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: the LOGiC trial. ASCO Meeting Abstracts 2013; 31: abstract LBA4001.
117. Tabernero J, Hoff PM, Shen L, et al., Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: an international phase III study (JACOB). ASCO Meeting Abstracts 2013; 31: abstract TPS4150.
118. Marchiò C, Lambros MB, Gugliotta P, et al., Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009; 219: 16-24.
119. Turner NC, Reis-Filho JS,. Genetic heterogeneity and cancer drug resistance. Lancet Oncol 2012; 13: e178-e185.
120. Aparicio S, Caldas C,. The implications of clonal genome evolution for cancer medicine. N Engl J Med 2013; 368: 842-851.
121. Geretti E, Paragas V, Onsum M, et al., Quantification of HER2 expression at the single cell level and HER2 intratumoral heterogeneity of breast cancer tissue samples using automated image analysis. Cancer Res 2012; 72: abstract P1-07-03.
122. Wickham T, Futch K,. A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive breast cancer. Cancer Res 2012; 72: abstract P5-18-09.
123. Owonikoko TK, Khuri FR,. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book 2013; 395-401.
124. Baselga J, Campone M, Piccart M, et al., Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529.
125. Gonzalez-Angulo AM, Juric D, Argiles G, et al., Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: results from the first-in-human study. ASCO Meeting Abstracts 2013; 31: 2531.
126. Juric D, Krop I, Ramanathan RK, et al., GDC-0032, a beta isoform-sparing PI3K inhibitor: results of a first-in-human phase Ia dose escalation study. AACR Annual Meeting 2013; abstract LB-64.
127. Burstein HJ, Sun Y, Dirix LY, et al., Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010; 28: 1301-1307.